Scholarlink

Background <p>Vestibular migraine (VM) is the second most common cause of episodic vertigo worldwide, yet effective therapeutic options remain limited. This study aimed to assess the clinical effectiveness of rimegepant in patients with VM.</p> Methods <p>A total of 33 VM cases were enrolled in this multicenter, prospective self-controlled cohort study, screened from an initial pool of 106 patients. Participants were orally administered rimegepant at 75&#xa0;mg every other day as a preventive therapy. Mean 4-week days of vestibular symptom or headache, along with Dizziness Handicap Inventory (DHI), Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9), Headache Impact Test-6 (HIT-6), Vertigo Symptom Scale–Short Form (VSS-SF), Activities-specific Balance Confidence Scale (ABC) scores, and hearing sensitivities were compared between pre-dosing and postdosing of rimegepant over a 4-week follow-up.</p> Results <p>At baseline, participants exhibited a high symptom burden, with elevated DHI, VSS-SF, GAD-7, PHQ-9, and HIT-6 scores and low ABC scores. After rimegepant treatment, there were substantial reductions in monthly vestibular symptom days and headache days (differences: vestibular symptoms, -8.48; headache, -5.88). Totally 63.6% and 70.4% of the patients experienced a 50% reduction in vestibular symptom days and headache days, respectively. Notably, these improvements were already apparent at 2 weeks, indicating early onset of efficacy. Additionally, rimegepant treatment led to significant improvements in vestibular function (differences: DHI, -27.33; VSS-SF, -6.21), psychological status (differences: GAD-7, -3.33; PHQ-9, -3.33), and quality of life (differences: HIT-6, -11.27; ABC, 19.98). In the 22 participants who underwent baseline and 4-week hearing assessments, pure tone audiometry (PTA) results also indicated improvements in hearing.</p> Conclusions <p>Rimegepant provides relief of vestibular symptoms and improves psychological well-being and hearing in patients with VM, with efficacy evident as early as 2 weeks.</p> Trial registration <p>NCT04939922.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effectiveness of rimegepant in vestibular migraine: a prospective self-controlled cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月22日

查看全文
  • Jinyan Shao,
  • Jingxin Fu,
  • Mengting Zhou,
  • Zewei Ren,
  • Longxiang Li,
  • Lili Gao,
  • Yuhui Xia,
  • Zexian Zhao,
  • Mengna Yang,
  • Jiahuan He,
  • Siyuan Xue,
  • Guoming Wang,
  • Jiahui He,
  • Kaiming Liu

摘要

Background

Vestibular migraine (VM) is the second most common cause of episodic vertigo worldwide, yet effective therapeutic options remain limited. This study aimed to assess the clinical effectiveness of rimegepant in patients with VM.

Methods

A total of 33 VM cases were enrolled in this multicenter, prospective self-controlled cohort study, screened from an initial pool of 106 patients. Participants were orally administered rimegepant at 75 mg every other day as a preventive therapy. Mean 4-week days of vestibular symptom or headache, along with Dizziness Handicap Inventory (DHI), Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9), Headache Impact Test-6 (HIT-6), Vertigo Symptom Scale–Short Form (VSS-SF), Activities-specific Balance Confidence Scale (ABC) scores, and hearing sensitivities were compared between pre-dosing and postdosing of rimegepant over a 4-week follow-up.

Results

At baseline, participants exhibited a high symptom burden, with elevated DHI, VSS-SF, GAD-7, PHQ-9, and HIT-6 scores and low ABC scores. After rimegepant treatment, there were substantial reductions in monthly vestibular symptom days and headache days (differences: vestibular symptoms, -8.48; headache, -5.88). Totally 63.6% and 70.4% of the patients experienced a 50% reduction in vestibular symptom days and headache days, respectively. Notably, these improvements were already apparent at 2 weeks, indicating early onset of efficacy. Additionally, rimegepant treatment led to significant improvements in vestibular function (differences: DHI, -27.33; VSS-SF, -6.21), psychological status (differences: GAD-7, -3.33; PHQ-9, -3.33), and quality of life (differences: HIT-6, -11.27; ABC, 19.98). In the 22 participants who underwent baseline and 4-week hearing assessments, pure tone audiometry (PTA) results also indicated improvements in hearing.

Conclusions

Rimegepant provides relief of vestibular symptoms and improves psychological well-being and hearing in patients with VM, with efficacy evident as early as 2 weeks.

Trial registration

NCT04939922.